site stats

Shane schaffer cingulate

WebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry … WebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is an 18-year pharmaceutical industry …

Cingulate Company Profile: Stock Performance & Earnings

WebFeb 8, 2024 · Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a... Web20 hours ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed … calf umbilical hernia surgery https://trunnellawfirm.com

Cingulate Provides 2024 Clinical Plan for CTx-1301, an ... - BioSpace

WebAug 18, 2024 · Shane Schaffer, the CEO of Cingulate Therapeutics, said this weekend’s meeting of the company’s seven-member scientific advisory board will include experts from the United States, Canada and... WebDec 20, 2024 · Shane Schaffer, Chairman & CEO of Cingulate, Inc. CING, was a guest on Benzinga’s All Access on 12/16/22. Cingulate is a clinical-stage biopharmaceutical … WebJan 16, 2024 · Cingulate Therapeutics chairman and CEO Shane Schaffer said: “Before Cingulate Therapeutics embarks on the studies necessary to gain FDA approval, we’ve been able to gain valuable insight as to how our assets are expected to perform in-vivo. calf urinary tract infection

Cingulate Provides 2024 Clinical Plan for CTx-1301, an

Category:Cingulate Provides 2024 Clinical Plan for CTx-1301, an …

Tags:Shane schaffer cingulate

Shane schaffer cingulate

Cingulate Completes Fed/Fast Study Assessing Food Effect with …

WebPeople named Shane Schaffer. Find your friends on Facebook. Log in or sign up for Facebook to connect with friends, family and people you know. Log In. or. Sign Up. Shane … WebShane Schaffer posted on LinkedIn Shane Schaffer’s Post Shane Schaffer 1y Cingulate Inc. 1,079 followers 1y Cingulate® Provides 2024 Clinical Plan for CTx-1301, an Investigational...

Shane schaffer cingulate

Did you know?

WebJan 9, 2024 · Shane Schaffer, who earned a pharmacy degree at the University of Kansas, founded Cingulate in New Jersey in 2013 after talking with friends in the pharmaceutical … WebWho is Cingulate Headquarters 1901 W 47th Pl, Kansas City, Kansas, 66205, United States Phone Number (913) 942-2300 Website www.cingulate.com Revenue $19.2M Stock …

WebShared by Shane Schaffer Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD BioSpace Liked by Shane … WebOct 20, 2024 · Cingulate is headquartered in Kansas City. For more information visit Cingulate.com. Investor Contact: Thomas Dalton Vice President, Investor & Public Relations, Cingulate [email protected] ...

WebShane J Schaffer is Chairman/CEO/Co-Founder at Cingulate Inc. See Shane J Schaffer's compensation, career history, education, & memberships. WebMar 14, 2024 · Cingulate chairman and CEO Shane Schaffer said: “This agreement provides a clear path to commercialise CTx-1301, upon FDA approval, designed specifically to …

WebDec 20, 2024 · Shane Schaffer, Chairman & CEO of Cingulate, Inc. CING , was a guest on Benzinga’s All Access on 12/16/22. Cingulate is a clinical-stage biopharmaceutical company focused on the development...

WebCingulate said the agreement spans cross-functional services via an omnichannel marketing approach aimed at successfully managing pre-commercial support during its phase 3 trials and to... coaching requirementsWeb20 hours ago · Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of ... coaching rennesWebApr 5, 2024 · Cingulate chairman and CEO Shane Schaffer said: “We’re pleased with the speed in which our first cohort of this Phase III trial was able to be completed, … coaching requestWebShane Schaffer . The Cingulate Therapeutics Leadership Team possesses a unique combination of clinical, medical, financial, regulatory and commercial expertise, including: • Extensive pharmaceutical industry experience • 50-years of neuroscience clinical experience • Published over 200 peer-reviewed publications coaching requirements ohsaaWebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry … calfurn manufacturing philippines incWebFeb 15, 2024 · Cingulate Inc. today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2024, at 10:30 a.m. ET. ... Cingulate’s presentation will be available by request to Aegis for the duration of the conference, from February 23 through ... coaching requirements in paWebAug 11, 2024 · Aug 11, 2024 Cingulate Inc. Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update ... (ADHD) and anxiety could benefit from the true once-daily medications we are advancing now,” said Shane J. Schaffer, Cingulate Chairman & CEO. Schaffer continued, “Capital is imperative to any clinical-stage company’s ... coaching research questions